Kyowa Kirin Co., Ltd

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$436Kgeneral payments (2019-2025)
$0.00research payments (2019-2025)
71clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $187K
2020 $72K
2021 $16K
2022 $80K
2023 $11K
2024 $41K
2025 $29K

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Nephrology (Internal Medicine) $111K
Medical Oncology $77K
Family Medicine $70K
Neurology (Psychiatry & Neurology) $55K
Dermatology $32K
Endocrinology, Diabetes & Metabolism $19K

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Mizra Rahman Plymouth Meeting, PA Family Medicine $70,345.76
Naoto Ueno Honolulu, HI Medical Oncology $67,777.21
Harold Feldman Philadelphia, PA Nephrology (Internal Medicine) $46,230.97
Stuart Isaacson Boca Raton, FL Neurology (Psychiatry & Neurology) $35,906.05
Eugene Rhee Boston, MA Nephrology (Internal Medicine) $19,532.99
Karl Insogna New Haven, CT Endocrinology, Diabetes & Metabolism $18,591.55
Tarek Ashkar Indianapolis, IN Internal Medicine $18,047.85
Stephan Grupp Philadelphia, PA Pediatric Hematology-Oncology $17,766.68
Kathrine Tuttle Spokane, WA Nephrology (Internal Medicine) $15,868.47
Bruce Robinson Ann Arbor, MI Nephrology (Internal Medicine) $11,727.98

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.